JP2010514834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514834A5 JP2010514834A5 JP2009544475A JP2009544475A JP2010514834A5 JP 2010514834 A5 JP2010514834 A5 JP 2010514834A5 JP 2009544475 A JP2009544475 A JP 2009544475A JP 2009544475 A JP2009544475 A JP 2009544475A JP 2010514834 A5 JP2010514834 A5 JP 2010514834A5
- Authority
- JP
- Japan
- Prior art keywords
- derivative
- cyclosporin
- formula
- immunosuppressive
- immunosuppressive cyclosporin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 20
- 230000001506 immunosuppresive Effects 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010036949 Cyclosporine Proteins 0.000 claims 4
- 102100011563 LAMA2 Human genes 0.000 claims 4
- 101700027052 LAMA2 Proteins 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims 4
- 206010028640 Myopathy Diseases 0.000 claims 3
- 201000010770 muscular disease Diseases 0.000 claims 3
- 201000009623 myopathy Diseases 0.000 claims 3
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 208000006304 Bethlem myopathy Diseases 0.000 claims 1
- 229940119017 Cyclosporine Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004065 mitochondrial dysfunctions Effects 0.000 claims 1
Claims (13)
- 式Iの非免疫抑制性シクロスポリンA誘導体の使用であって、ウールリッヒ型先天筋ジストロフィー又はベツレムミオパシーの処置を目的とした医薬の製造のための、使用。
- 非免疫抑制性シクロスポリンA誘導体が、式IIのシクロスポリン誘導体である、請求項4に記載の使用。
- 非免疫抑制性シクロスポリンA誘導体が、式IIIの非免疫抑制性シクロスポリン[D−MeAla]3−[EtVal]4−CsAである、請求項4又は5に記載の使用。
- 患者における、ウールリッヒ型先天筋ジストロフィー又はベツレムミオパシーの処置のための方法であって、式Iの非免疫抑制性シクロスポリンA誘導体の有効量を患者に投与することを含んでなる、方法。
- 非免疫抑制性シクロスポリンA誘導体が、式IIのシクロスポリン誘導体である、請求項7に記載の方法。
- 非免疫抑制性シクロスポリンA誘導体が、式IIIの非免疫抑制性シクロスポリン[D−MeAla]3−[EtVal]4−CsAである、請求項7又は8に記載の方法。
- ウールリッヒ型先天筋ジストロフィー又はベツレムミオパシーの処置のための医薬組成物であって、式Iの非免疫抑制性シクロスポリンA誘導体の有効量、医薬的に許容可能な担体を含んでなるとともに、任意に賦形剤及び希釈剤を含んでなる、医薬組成物。
- 非免疫抑制性シクロスポリンA誘導体が、式IIのシクロスポリン誘導体である、請求項10に記載の医薬組成物。
- 非免疫抑制性シクロスポリンA誘導体が、式IIIの非免疫抑制性シクロスポリン[D−MeAla]3−[EtVal]4−CsAである、請求項10又は11に記載の医薬組成物。
- 追加の活性成分をさらに含んでなる、請求項10〜12のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87841407P | 2007-01-04 | 2007-01-04 | |
US60/878,414 | 2007-01-04 | ||
PCT/IB2008/000003 WO2008084368A2 (en) | 2007-01-04 | 2008-01-03 | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010514834A JP2010514834A (ja) | 2010-05-06 |
JP2010514834A5 true JP2010514834A5 (ja) | 2011-02-17 |
JP5801534B2 JP5801534B2 (ja) | 2015-10-28 |
Family
ID=39514754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009544475A Expired - Fee Related JP5801534B2 (ja) | 2007-01-04 | 2008-01-03 | ウールリッヒ型先天筋ジストロフィーの処置のための、非免疫抑制性シクロスポリン |
Country Status (12)
Country | Link |
---|---|
US (1) | US8450281B2 (ja) |
EP (1) | EP2124992A2 (ja) |
JP (1) | JP5801534B2 (ja) |
CN (2) | CN105056207A (ja) |
AU (1) | AU2008204344B2 (ja) |
BR (1) | BRPI0806265A2 (ja) |
CA (1) | CA2674296C (ja) |
HK (1) | HK1210951A1 (ja) |
IL (1) | IL199674A (ja) |
MX (1) | MX2009007045A (ja) |
RU (1) | RU2462262C2 (ja) |
WO (1) | WO2008084368A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
AU2011214135B2 (en) | 2010-02-09 | 2014-07-31 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
WO2012085553A1 (en) | 2010-12-20 | 2012-06-28 | Biotica Technology Limited | Sanglifehrin derivatives and methods for their production |
JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
TW201350127A (zh) | 2012-05-07 | 2013-12-16 | Novartis Ag | C型肝炎病毒感染之新治療方法 |
AR090964A1 (es) | 2012-05-09 | 2014-12-17 | Novartis Ag | Proceso para la elaboracion de undecapeptidos ciclicos |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE95193T1 (de) * | 1987-06-17 | 1993-10-15 | Sandoz Ag | Cyclosporine und deren benutzung als arzneimittel. |
GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
JP2002512954A (ja) * | 1998-04-24 | 2002-05-08 | マイトコー | ミトコンドリア関連疾患を処置するための化合物および方法 |
ATE312843T1 (de) * | 1998-07-01 | 2005-12-15 | Debiopharm Sa | Neues cyclosporin mit verbesserter wirkung |
US6323039B1 (en) * | 1999-06-22 | 2001-11-27 | Mitokor | Compositions and methods for assaying subcellular conditions and processes using energy transfer |
US7368423B1 (en) | 2001-12-05 | 2008-05-06 | The Scripps Research Institute | Composition and method for treating chronic allograft rejection |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
-
2008
- 2008-01-03 EP EP08702176A patent/EP2124992A2/en not_active Withdrawn
- 2008-01-03 CN CN201510378165.7A patent/CN105056207A/zh active Pending
- 2008-01-03 RU RU2009129212/15A patent/RU2462262C2/ru not_active IP Right Cessation
- 2008-01-03 BR BRPI0806265-0A patent/BRPI0806265A2/pt not_active Application Discontinuation
- 2008-01-03 JP JP2009544475A patent/JP5801534B2/ja not_active Expired - Fee Related
- 2008-01-03 US US12/522,118 patent/US8450281B2/en not_active Expired - Fee Related
- 2008-01-03 CN CN200880001665A patent/CN101616683A/zh active Pending
- 2008-01-03 AU AU2008204344A patent/AU2008204344B2/en not_active Ceased
- 2008-01-03 CA CA2674296A patent/CA2674296C/en not_active Expired - Fee Related
- 2008-01-03 MX MX2009007045A patent/MX2009007045A/es active IP Right Grant
- 2008-01-03 WO PCT/IB2008/000003 patent/WO2008084368A2/en active Application Filing
-
2009
- 2009-07-02 IL IL199674A patent/IL199674A/en active IP Right Grant
-
2010
- 2010-05-20 HK HK15111764.4A patent/HK1210951A1/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010514834A5 (ja) | ||
RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
JP2009102342A5 (ja) | ||
AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
JP2010077141A5 (ja) | ||
CA2893959A1 (en) | Pharmaceutical compositions | |
Dorian | Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation | |
EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
JP2009280627A5 (ja) | ||
JP2016540738A5 (ja) | ||
JP2007532607A5 (ja) | ||
JP2016517888A5 (ja) | ||
JP2008044951A5 (ja) | ||
JP2008501753A5 (ja) | ||
JP2010174019A5 (ja) | ||
EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
JP2013501056A5 (ja) | ||
JP2008534503A5 (ja) | ||
JP2019515908A5 (ja) | ||
JP2008540405A5 (ja) | ||
US20220370360A1 (en) | Compositions for treating viral infections and methods for same | |
JP2013505233A5 (ja) | ||
JP2012522783A5 (ja) | ||
JP2006518731A5 (ja) | ||
RU2009129212A (ru) | Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха |